CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 572 enrolled
Drug / intervention
mRNA-1030 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05333289
NCT05333289Phase 2Completed
CompareCT.gov

Phase 1/2, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1020 and mRNA-1030 Candidate Seasonal Influenza Vaccines in Healthy Adults

ModernaTX, Inc.·interventional·Posted Apr 18, 2022·Updated Feb 1, 2024

In Brief

A Phase 2 clinical trial evaluating mRNA-1030, mRNA-1020, and 2 other interventions for Seasonal Influenza. Completed, enrolled 572 participants across 15 sites.

Detailed Summary

The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1020, mRNA-1030, and mRNA-1010 vaccines against vaccine-matched influenza A and B strains.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Influenza
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedApr 18, 2022
Enrollment StartApr 6, 2022
Primary CompletionNov 22, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.2 years ago

Interventions

mRNA-1030biological

Sterile liquid for injection

mRNA-1020biological

Sterile liquid for injection

mRNA-1010biological

Sterile liquid for injection

Active Comparatorbiological

Sterile liquid for injection